Figure 5From: KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cellsDifferential effect of ARRY-520 and Paclitaxel on cytokine profile in Type I EOC cells. Cells were treated with ARRY-520 (0.03, 0.3, 3 μM) or Paclitaxel for (0.2, 2, 20 μM) for 48 hrs and levels of secreted cytokines/chemokines were determined using xMAP technology.Back to article page